LACOSAMIDE 10 mg /Ml Solution

Sergey Ilyasov

PsychiatryNeurology7 years of experience

Dr Sergey Ilyasov is an experienced neurologist and qualified psychiatrist who provides online consultations for adults and adolescents. Combining deep neurological expertise with a modern psychiatric approach, he ensures comprehensive diagnostics and effective treatment for a wide range of conditions affecting both physical and mental health.

Dr. Ilyasov helps patients in the following cases:

Chronic headaches (migraine, tension-type headache), back pain, neuropathic pain, dizziness, numbness in limbs, coordination disorders.
Anxiety disorders (panic attacks, generalized anxiety disorder), depression (including atypical and treatment-resistant forms), sleep disturbances (insomnia, hypersomnia, nightmares), stress, burnout.
Chronic pain syndromes and psychosomatic symptoms (e.g., irritable bowel syndrome related to stress, vegetative-vascular dystonia).
Behavioral disorders and concentration difficulties in adolescents (including ADHD, autism spectrum disorders), nervous tics.
Memory impairments, phobias, obsessive-compulsive disorder (OCD), emotional swings, and support for post-traumatic stress disorder (PTSD).

Thanks to his dual specialization in neurology and psychiatry, Dr Sergey Ilyasov offers integrated and evidence-based care for complex conditions requiring a multidisciplinary approach. His consultations focus on accurate diagnosis, development of an individualized treatment plan (including pharmacotherapy and psychotherapeutic methods), and long-term support adapted to each patient's unique needs.

Book an online consultation with Dr. Sergey Ilyasov to receive qualified assistance and improve your well-being today.

Book a video appointment

€106

More times

This page is for general information. Consult a doctor for personal advice. Call emergency services if symptoms are severe.

How to use Lacosamide Fresenius Kabi

Contents of the leaflet

Package Leaflet: Information for the Patient
Lacosamide Fresenius Kabi, 10 mg/ml, Solution for Infusion
1. Read the Package Leaflet Carefully Before Using the Medication, as it Contains Important Information for the Patient.
2. Table of Contents of the Package Leaflet
What is Lacosamide Fresenius Kabi and What is it Used For
1. What is Lacosamide Fresenius Kabi
2. What is Lacosamide Fresenius Kabi Used For
Important Information Before Using Lacosamide Fresenius Kabi
How to Use Lacosamide Fresenius Kabi
Possible Side Effects
How to Store Lacosamide Fresenius Kabi
Package Contents and Other Information

Package Leaflet: Information for the Patient

Lacosamide Fresenius Kabi, 10 mg/ml, Solution for Infusion

Lacosamide

Read the Package Leaflet Carefully Before Using the Medication, as it Contains Important Information for the Patient.

Keep this package leaflet, you may need to read it again.

In case of any doubts, consult a doctor or pharmacist.

If the patient experiences any side effects, including those not listed in this package leaflet, they should inform their doctor or pharmacist. See section 4.

Table of Contents of the Package Leaflet

1. What is Lacosamide Fresenius Kabi and What is it Used For
2. Important Information Before Using Lacosamide Fresenius Kabi
3. How to Use Lacosamide Fresenius Kabi
4. Possible Side Effects
5. How to Store Lacosamide Fresenius Kabi
6. Package Contents and Other Information

Not sure if this medicine is right for you?

Discuss your symptoms and treatment with a doctor online.

1. What is Lacosamide Fresenius Kabi and What is it Used For

What is Lacosamide Fresenius Kabi

Lacosamide Fresenius Kabi contains lacosamide. It belongs to a group of medications called "antiepileptic drugs", which are used to treat epilepsy.

This medication has been prescribed by a doctor to reduce the number of seizures.

What is Lacosamide Fresenius Kabi Used For

Lacosamide Fresenius Kabi is used:

as monotherapy and in combination with other antiepileptic medications in adults, adolescents, and children from 2 years of age for the treatment of a type of epilepsy characterized by partial seizures and secondary generalized seizures. In this type of epilepsy, seizures initially affect only one side of the brain but may then spread to other areas on both sides of the brain.
in combination with other antiepileptic medications in adults, adolescents, and children from 4 years of age for the treatment of primary generalized tonic-clonic seizures (grand mal seizures involving loss of consciousness) in patients with generalized idiopathic epilepsy (a type of epilepsy considered to have a genetic basis).

2. Important Information Before Using Lacosamide Fresenius Kabi

When Not to Use Lacosamide Fresenius Kabi

if the patient is allergic to lacosamide or any of the other ingredients of this medication (listed in section 6). In case of doubt about the existence of an allergy, consult a doctor.

if the patient has a certain type of heart rhythm disorder (called second or third degree atrioventricular block).
If any of the above situations apply to the patient, they should not use Lacosamide Fresenius Kabi. In case of doubt, before using this medication, consult a doctor or pharmacist.

Warnings and Precautions

Before starting treatment with Lacosamide Fresenius Kabi, the patient should consult a doctor if:

the patient thinks about self-harm or suicide. In some patients treated with antiepileptic medications, such as lacosamide, thoughts of self-harm or suicidal thoughts have occurred. If such thoughts occur, the patient should immediately contact their doctor.

the patient has a heart condition that affects the heart rhythm - often it is slowed, accelerated, or irregular (i.e., atrioventricular block, atrial fibrillation, and atrial flutter).

the patient has severe heart disease, such as heart failure or has had a heart attack.

the patient often experiences dizziness or falls. Lacosamide Fresenius Kabi may cause dizziness, which can increase the risk of accidental injury or falls.
Therefore, caution should be exercised until the body gets used to the action of the medication.
If any of the above situations occur (or there are doubts about them), before starting treatment with Lacosamide Fresenius Kabi, the patient should consult a doctor or pharmacist.
If the patient is using Lacosamide Fresenius Kabi and experiences new types of seizures or worsening of existing seizures, they should inform their doctor.
If the patient is using Lacosamide Fresenius Kabi and experiences symptoms of abnormal heart rhythm (such as slow, fast, irregular heartbeat, palpitations, shortness of breath, dizziness, fainting), they should immediately contact their doctor (see section 4).

Children

Lacosamide is not recommended for children under 2 years of age with epilepsy characterized by partial seizures, and it is not recommended for children under 4 years of age with primary generalized tonic-clonic seizures. The efficacy and safety of the medication in this age group are not yet known.

Lacosamide Fresenius Kabi and Other Medications

The patient should inform their doctor or pharmacist about all medications they are currently using or have recently used, as well as any medications they plan to use.
Particularly, the patient should inform their doctor or pharmacist about the use of any of the following medications that affect heart function, as lacosamide also affects heart function:

medications used for heart conditions;

medications that may cause prolongation of the PQ interval (visible in the electrocardiogram EKG), such as medications used to treat epilepsy or pain, e.g., carbamazepine, lamotrigine, or pregabalin;

medications used in the treatment of certain types of heart rhythm disorders or heart failure.
If any of the above situations occur (or there are doubts about them), before starting treatment with Lacosamide Fresenius Kabi, the patient should consult a doctor or pharmacist.
The patient should also inform their doctor or pharmacist about the use of any of the following medications, as they may decrease or increase the effectiveness of Lacosamide Fresenius Kabi:

medications used for fungal infections, such as fluconazole, itraconazole, or ketoconazole;
medications used for HIV infection, such as ritonavir;
medications used for bacterial infections, such as clarithromycin or rifampicin;
a herbal remedy used for mild anxiety and depression - St. John's Wort. If any of the above situations occur (or there are doubts about them), before starting treatment with Lacosamide Fresenius Kabi, the patient should consult a doctor or pharmacist.

Lacosamide Fresenius Kabi with Alcohol

For safety reasons, the patient should not drink alcohol while using Lacosamide Fresenius Kabi.

Pregnancy and Breastfeeding

Women of childbearing age should discuss the use of contraception with their doctor.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medication.
Lacosamide Fresenius Kabi is not recommended during pregnancy or breastfeeding, as its effect on the course of pregnancy and the unborn child or newborn is not known.
It is also not known whether Lacosamide Fresenius Kabi passes into human milk. The patient should urgently consult their doctor if they become pregnant or plan to become pregnant. The doctor will help decide whether Lacosamide Fresenius Kabi can be used.
The patient should not stop treatment without consulting their doctor, as this may increase the frequency of seizures. The severity of the mother's symptoms may also harm the child.

Driving and Operating Machines

The patient should not drive a car, ride a bike, or use tools or operate machines until they are sure how the medication affects them. This is because Lacosamide Fresenius Kabi may cause dizziness or blurred vision.

Lacosamide Fresenius Kabi Contains Sodium

The medication contains 59.8 mg of sodium (the main component of table salt) in each vial, which corresponds to 3% of the recommended maximum daily sodium intake for an adult.

Started taking the medicine and have questions?

Discuss your symptoms and treatment with a doctor online.

3. How to Use Lacosamide Fresenius Kabi

This medication should always be used as directed by a doctor or pharmacist. In case of doubt, the patient should consult a doctor or pharmacist.

Using Lacosamide Fresenius Kabi

Treatment with Lacosamide Fresenius Kabi can be started with:

oral administration or
intravenous infusion (iv.), during which the doctor or nurse administers the medication into the patient's vein. The infusion time is from 15 to 60 minutes. Intravenous infusion is usually used for a short time when the medication cannot be administered orally. The doctor will decide how many days the patient will receive infusions. There are data on the use of lacosamide in infusion twice a day for up to 5 days. In long-term treatment, lacosamide is used in tablets and syrup.

When changing the method of administration from infusion to oral (and vice versa), the total daily dose and frequency of administration remain unchanged.

Lacosamide should be used twice a day (approximately every 12 hours).

The medication should be used at approximately the same time every day.

What Dose to Use

The following are the usual recommended doses of lacosamide for patients of different age groups and body weights. The doctor may prescribe a different dose if the patient has kidney or liver function disorders.

Adolescents and Children with a Body Weight of at Least 50 kg and Adults

Using Lacosamide Fresenius Kabi alone

The usual initial dose of lacosamide is 50 mg twice a day.

Treatment can also be started with a dose of 100 mg of lacosamide twice a day.

The doctor may increase the administered dose twice a day by 50 mg every week until a maintenance dose is reached, which is from 100 mg to 300 mg twice a day.
Using Lacosamide Fresenius Kabi with other antiepileptic medications

The usual initial dose of lacosamide is 50 mg twice a day.

The doctor may increase the administered dose twice a day by 50 mg every week until a maintenance dose is reached, which is from 100 mg to 200 mg twice a day.

In patients with a body weight of at least 50 kg, the doctor may decide to start administering lacosamide with a single loading dose of 200 mg. Then, after 12 hours, the patient will start using a fixed maintenance dose.

Children and Adolescents with a Body Weight Below 50 kg

Using in the treatment of partial seizures:note that lacosamide is not recommended for use in children under 2 years of age.

Using in the treatment of primary generalized tonic-clonic seizures: note that lacosamide is not recommended for use in children under 4 years of age.
Using Lacosamide Fresenius Kabi alone

The doctor will determine the dose of lacosamide based on the patient's body weight.

The usual initial dose of lacosamide is 1 mg (0.1 ml) per kilogram of body weight, twice a day.

The doctor may increase the administered dose twice a day by 1 mg (0.1 ml) per kilogram of body weight every week until a maintenance dose is reached.

The dosage tables, including the recommended maximum dose, are presented below for informational purposes only. The doctor will calculate the appropriate dose for the patient.
Doses used twice a dayin children from 2 years of age with a body weight from 10 kg to
below 40 kg:
Doses used twice a dayin children and adolescents with a body weight from 40 kg to
below 50 kg:
Using Lacosamide Fresenius Kabi with other antiepileptic medications

The doctor will determine the appropriate dose of lacosamide based on the patient's body weight.

In children and adolescents with a body weight from 10 kg to below 50 kg, the usual initial dose is 1 mg (0.1 ml) per kilogram of body weight, twice a day.

Body Weight	Week 1. Initial Dose: 0.1 ml/kg body weight.	Week 2. 0.2 ml/kg body weight.	Week 3. 0.3 ml/kg body weight.	Week 4. 0.4 ml/kg body weight.	Week 5. 0.5 ml/kg body weight.	Week 6. Maximum Recommended Dose: 0.6 ml/kg body weight.
10 kg	1 ml	2 ml	3 ml	4 ml	5 ml	6 ml
15 kg	1.5 ml	3 ml	4.5 ml	6 ml	7.5 ml	9 ml
20 kg	2 ml	4 ml	6 ml	8 ml	10 ml	12 ml
25 kg	2.5 ml	5 ml	7.5 ml	10 ml	12.5 ml	15 ml
30 kg	3 ml	6 ml	9 ml	12 ml	15 ml	18 ml
35 kg	3.5 ml	7 ml	10.5 ml	14 ml	17.5 ml	21 ml

Body Weight	Week 1. Initial Dose: 0.1 ml/kg body weight.	Week 2. 0.2 ml/kg body weight.	Week 3. 0.3 ml/kg body weight.	Week 4. 0.4 ml/kg body weight.	Week 5. Maximum Recommended Dose: 0.5 ml/kg body weight.
40 kg	4 ml	8 ml	12 ml	16 ml	20 ml
45 kg	4.5 ml	9 ml	13.5 ml	18 ml	22.5 ml

The doctor may increase the administered dose twice a day by 1 mg (0.1 ml) per kilogram of body weight every week until a maintenance dose is reached.

The dosage tables, including the recommended maximum dose, are presented below for informational purposes only. The doctor will calculate the appropriate dose for the patient.
Doses used twice a dayin children from 2 years of age with a body weight from 10 kg to
below 20 kg:
Doses used twice a dayin children and adolescents with a body weight from 20 kg to
below 30 kg:
Doses used twice a dayin children and adolescents from 4 years of age with a body weight from

30 kg to below 50 kg:

Stopping Lacosamide Fresenius Kabi

If the doctor decides to stop using Lacosamide Fresenius Kabi, they will gradually reduce the dose of the medication. This is to prevent the recurrence of epilepsy or its exacerbation.
In case of doubts related to the use of this medication, the patient should consult a doctor or pharmacist.

4. Possible Side Effects

Like all medications, Lacosamide Fresenius Kabi can cause side effects, although not everybody gets them.
Side effects from the nervous system, such as dizziness, may be stronger after a single loading dose.

The Patient Should Inform Their Doctor or Pharmacist if They Experience Any of the Following Symptoms:

Very Common(may occur more often than in 1 in 10 patients):

headache;

dizziness or nausea (vomiting);

double vision.
Common(may occur less often than in 1 in 10 patients):

short muscle jerks or muscle groups (myoclonic seizures);

Body Weight	Week 1. Initial Dose: 0.1 ml/kg	Week 2. 0.2 ml/kg body weight.	Week 3. 0.3 ml/kg body weight.	Week 4. 0.4 ml/kg body weight.	Week 5. 0.5 ml/kg body weight.	Week 6. Maximum Recommended Dose: 0.6 ml/kg body weight.
10 kg	1 ml	2 ml	3 ml	4 ml	5 ml	6 ml
15 kg	1.5 ml	3 ml	4.5 ml	6 ml	7.5 ml	9 ml

Body Weight	Week 1. Initial Dose: 0.1 ml/kg body weight.	Week 2. 0.2 ml/kg body weight.	Week 3. 0.3 ml/kg body weight.	Week 4. 0.4 ml/kg body weight.	Week 5. Maximum Recommended Dose: 0.5 ml/kg body weight.
20 kg	2 ml	4 ml	6 ml	8 ml	10 ml
25 kg	2.5 ml	5 ml	7.5 ml	10 ml	12.5 ml

Body Weight	Week 1. Initial Dose: 0.1 ml/kg body weight.	Week 2. 0.2 ml/kg body weight.	Week 3. 0.3 ml/kg body weight.	Week 4. Maximum Recommended Dose: 0.4 ml/kg body weight.
30 kg	3 ml	6 ml	9 ml	12 ml
35 kg	3.5 ml	7 ml	10.5 ml	14 ml
40 kg	4 ml	8 ml	12 ml	16 ml
45 kg	4.5 ml	9 ml	13.5 ml	18 ml

difficulty with coordination or walking;

balance disorders, tremors, numbness (paresthesia), muscle cramps, tendency to fall or bruise;

memory disorders, thinking disorders, difficulty finding words, confusion;

rapid uncontrolled eye movements (nystagmus), blurred vision;

a feeling of spinning (dizziness), a feeling of being drunk;

vomiting, dry mouth, constipation, indigestion, excess gas in the stomach or intestines, diarrhea;

decreased sensation and sensitivity to stimuli, speech difficulties, attention disorders;

ringing in the ears, such as buzzing, ringing, or whistling;

irritability, difficulty sleeping, depression;

drowsiness, fatigue, or weakness (asthenia);

itching, rash.
Uncommon(may occur less often than in 1 in 100 patients):

slow heart rate, palpitations, irregular heartbeat, or other changes in heart electrical activity (conduction disorders);

excessive well-being, seeing and (or) hearing non-existent things;

allergic reaction after taking the medication, hives;

abnormal liver blood test results (indicating abnormal liver function, liver damage);

thoughts of self-harm or suicide or attempted suicide: the patient should immediately inform their doctor;

feeling angry or agitated;

thinking disorders or loss of contact with reality;

severe allergic reactions causing swelling of the face, throat, hands, feet, ankles, or lower legs;

fainting;

involuntary movements (dyskinesia).
Frequency Not Known(frequency cannot be estimated from the available data):

abnormal rapid heart rhythm (tachyarrhythmia);

sore throat, high fever, and frequent infections. Blood tests may show a significant decrease in the number of a certain type of white blood cell (agranulocytosis);

severe skin reaction, which may be accompanied by high fever and flu-like symptoms, rash on the face, spreading rash, swollen lymph nodes (enlarged lymph nodes). Blood tests may show increased liver enzyme levels and an increased number of one type of white blood cell (eosinophilia);

widespread rash with blisters and peeling skin, occurring mainly in the area of the mouth, eyes, nose, and genitals (Stevens-Johnson syndrome) and a more severe form of rash causing skin peeling over more than 30% of the body surface (toxic epidermal necrolysis);

seizures.

Local side effects may occur, such as:
Common(may occur less often than in 1 in 10 patients):

Pain, discomfort, or irritation at the injection site.
Uncommon(may occur less often than in 1 in 100 patients):

Redness at the injection site.

Additional Side Effects in Children

Additional side effects in children included fever, runny nose (nasopharyngitis), sore throat (pharyngitis), decreased appetite, behavioral changes, the child does not behave as usual (abnormal behavior), and lack of energy (lethargy). Drowsiness is a very common side effect in children and may occur in more than 1 in 10 children.

Reporting Side Effects

If side effects occur, including those not listed in this package leaflet, the patient should inform their doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety Monitoring of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
phone: +48 22 49 21 301
fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
Reporting side effects will help to gather more information on the safety of the medication.

5. How to Store Lacosamide Fresenius Kabi

The medication should be stored out of sight and reach of children.
Do not use this medication after the expiry date stated on the carton and vial after "EXP". The expiry date refers to the last day of the month stated.
Do not store above 25°C.
Each vial of Lacosamide Fresenius Kabi should be used only once (single use).
Unused portions of the solution should be discarded.
Only clear solutions without visible particles and color changes should be used.
Medications should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medications they no longer use. This will help protect the environment.

6. Package Contents and Other Information

What Lacosamide Fresenius Kabi Contains

The active substance of the medication is lacosamide.
1 ml of the solution for infusion contains 10 mg of lacosamide.
1 vial contains 20 ml of the solution for infusion, which corresponds to 200 mg of lacosamide.

The other ingredients are sodium chloride, hydrochloric acid 0.86%, and water for injections.

What Lacosamide Fresenius Kabi Looks Like and What the Package Contains

Lacosamide Fresenius Kabi, 10 mg/ml, solution for infusion is a clear, colorless solution.
Lacosamide Fresenius Kabi is available in packages: 1 vial, 5 vials, and 10 vials. Each vial contains 20 ml of the solution for infusion.
Not all package sizes may be marketed.

Marketing Authorization Holder

Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw

Manufacturer

Fresenius Kabi Deutschland GmbH
Pfingstweide 53
61169 Friedberg
Germany
Labesfal - Laboratórios Almiro, S.A.
Zona Industrial do Lagedo
3465-157 Santiago de Besteiros
Portugal
To obtain more detailed information, the patient should contact the marketing authorization holder:
Fresenius Kabi Polska Sp. z o.o.
Al. Jerozolimskie 134
02-305 Warsaw
phone: +48 22 345 67 89

This Medication is Authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) Under the Following Names:

Member State	Medication Name
Austria	Lacosamid Fresenius Kabi 10 mg/ml Infusionslösung
Bulgaria	Lacosamide Fresenius Kabi 10 mg/ml solution for infusion
Cyprus	Lacosamide Fresenius Kabi 10mg/ml διάλυμα για έγχυση
Czech Republic	Lacosamide Fresenius Kabi
Estonia	Lacosamide Fresenius Kabi
Finland	Lacosamide Fresenius Kabi 10 mg/ml solution for infusion
France	LACOSAMIDE FRESENIUS KABI 10 mg/ml, solution pour perfusion
Greece	Lacosamide Fresenius Kabi 10mg/ml solution for infusion
Spain	Lacosamida Fresenius Kabi 10 mg/ml solución para perfusión EFG
Ireland	Lacosamide Fresenius Kabi 10mg/ml solution for infusion
Liechtenstein	Lacosamid Fresenius Kabi 10 mg/ml Infusionslösung
Lithuania	Lacosamide Fresenius Kabi 10 mg/ml infuzinis tirpalas
Luxembourg	Lacosamide Fresenius Kabi 10 mg/ml Infusionslösung
Latvia	Lacosamide Fresenius Kabi 10 mg/ml šķīdums infūzijām
Malta	Lacosamide Fresenius Kabi 10 mg/ml solution for infusion
Germany	Lacosamide Fresenius Kabi 10 mg/ml Infusionslösung
Norway	Lacosamide Fresenius Kabi
Poland	Lacosamide Fresenius Kabi
Portugal	Lacosamida Fresenius Kabi
Romania	Lacosamid Fresenius Kabi 10 mg/ml soluție perfuzabilă
Slovakia	Lacosamide Fresenius Kabi 10 mg/ml
Hungary	Lacosamide Fresenius Kabi 10 mg/ml oldatos infúzió
United Kingdom (Northern Ireland)	Lacosamide Fresenius Kabi 10 mg/ml solution for infusion
Italy	Lacosamide Fresenius Kabi

Date of Last Revision of the Package Leaflet:23.12.2023
--------------------------------------------------------------------------------------------------------------------

Information Intended for Healthcare Professionals Only:

Each vial of Lacosamide Fresenius Kabi should be used only once (single use).
Unused portions of the solution should be discarded (see section 3).
Lacosamide Fresenius Kabi can be administered without prior dilution or can be diluted with the following solutions: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%), or Ringer's solution with lactate.
For the diluted medication, chemical and physical stability has been demonstrated for 7 days at a temperature up to 25°C and stored in glass containers or bags (PVC or non-PVC).
From a microbiological point of view, the medication should be used immediately. If not used immediately, the responsibility for the storage time and conditions lies with the user. The solution should not be stored for more than 24 hours at a temperature between 2°C and 8°C, unless it was prepared in controlled and validated aseptic conditions.

Country of registration
Poland
Dosage form
Solution, 10 mg/ml
ATC code
N03AX18
Active substance
lacosamide
Prescription required
Yes
Manufacturer
Labesfal - Laboratórios Almiro, S.A.
Importer
Fresenius Kabi Deutschland GmbH Labesfal - Laboratórios Almiro, S.A.
This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
Alternatives to Lacosamide Fresenius Kabi
Lackepila
Dosage form: Tablets, 50 mg
Active substance: lacosamide
Manufacturer: Symphar Sp. z o.o.
Prescription required
Lackepila
Dosage form: Tablets, 100 mg
Active substance: lacosamide
Manufacturer: Symphar Sp. z o.o.
Prescription required
Lackepila
Dosage form: Tablets, 150 mg
Active substance: lacosamide
Manufacturer: Symphar Sp. z o.o.
Prescription required

Online doctors for Lacosamide Fresenius Kabi

Discuss questions about Lacosamide Fresenius Kabi, including use, safety considerations and prescription review, subject to medical assessment and local regulations.

5.0(14)

Sergey Ilyasov

PsychiatryNeurology7 years of experience

Dr. Ilyasov helps patients in the following cases:

Chronic headaches (migraine, tension-type headache), back pain, neuropathic pain, dizziness, numbness in limbs, coordination disorders.
Anxiety disorders (panic attacks, generalized anxiety disorder), depression (including atypical and treatment-resistant forms), sleep disturbances (insomnia, hypersomnia, nightmares), stress, burnout.
Chronic pain syndromes and psychosomatic symptoms (e.g., irritable bowel syndrome related to stress, vegetative-vascular dystonia).
Behavioral disorders and concentration difficulties in adolescents (including ADHD, autism spectrum disorders), nervous tics.
Memory impairments, phobias, obsessive-compulsive disorder (OCD), emotional swings, and support for post-traumatic stress disorder (PTSD).

Book an online consultation with Dr. Sergey Ilyasov to receive qualified assistance and improve your well-being today.

Book a video appointment

€106

More times

5.0(3)

Ekaterina Agapova

NeurologyPain medicine9 years of experience

Dr. Ekaterina Agapova is a neurologist specialising in the diagnosis and treatment of neurological conditions and chronic pain. She provides online consultations for adults, combining evidence-based medicine with a personalised approach.

She offers expert care for:

Headaches and migraines, including tension-type and cluster headaches.
Neck and back pain, both acute and chronic.
Chronic pain syndromes – fibromyalgia, neuropathic pain, post-traumatic pain.
Mononeuropathies – carpal tunnel syndrome, trigeminal neuralgia, facial nerve palsy.
Polyneuropathies – diabetic, toxic, and other types.
Multiple sclerosis – diagnosis, monitoring, long-term support.
Dizziness and coordination disorders.
Sleep disturbances – insomnia, daytime sleepiness, fragmented sleep.
Anxiety, depression, and stress-related conditions.

Dr. Agapova helps patients manage complex neurological symptoms like pain, numbness, weakness, poor sleep, and emotional distress. Her consultations focus on accurate diagnosis, clear explanation of findings, and tailored treatment plans.

If you’re struggling with chronic pain, migraines, nerve disorders, or sleep problems, Dr. Agapova offers professional guidance to restore your well-being.

Book a video appointment

€61

More times

5.0(2)

Liubov Popova

NeurologyGeneral medicine7 years of experience

Dr. Liubov Popova is a neurologist and has been consulting adult patients in Valencia since 2019. She conducts consultations exclusively online, helping patients understand their neurological symptoms, identify possible causes of their complaints, and navigate the next steps in diagnosis and treatment.

Patients usually consult her with symptoms such as:

headache and migraine
dizziness
numbness in the limbs
sleep disorders
tremor
neck and back pain
Parkinson’s disease
as well as other complaints related to the nervous system

During the consultation, the doctor carefully analyzes the symptoms, medical history, and results of previously performed examinations in order to provide clear and well-grounded recommendations.

The doctor works with adult patients and provides consultations in Russian, English, and Spanish. In her practice, she pays special attention to ensuring that each consultation is not only professional but also comfortable and easy to understand for the patient, regardless of their location.

Book a video appointment

€86

More times

0.0(0)

New doctor

Tetiana Radchuk

PsychiatryNeurology11 years of experience

Tetiana Radchuk is a psychiatrist, psychotherapist and neurologist providing online consultations for adults experiencing mood disorders, anxiety disorders and neurological conditions affecting sleep, daily functioning and quality of life.

Her combined expertise in psychiatry, psychotherapy and neurology allows for a comprehensive assessment of both mental and neurological health, helping to develop an individualised treatment plan.

Areas of expertise

depression, low mood, fatigue and emotional burnout;
anxiety disorders, panic attacks, phobias and generalized anxiety disorder;
insomnia and other sleep disorders;
bipolar disorder and other mood disorders;
obsessive-compulsive disorder (OCD);
adult ADHD and autism spectrum disorder (ASD): assessment and ongoing care;
psychosomatic disorders, stress-related conditions and adjustment disorders;
headaches, migraine and autonomic nervous system disorders;
medication management, treatment adjustment and psychotherapeutic support.

Tetiana Radchuk combines evidence-based medicine with clinical expertise and a patient-centred approach. Assessment and treatment follow current clinical guidelines, with decisions made together with the patient according to their individual needs. Online consultations provide confidential and convenient access to professional mental health care.

Book a video appointment

€136

More times

Get Lacosamide Fresenius Kabi Prescription Online

Fill in a 2-min form

Tell us your symptoms, history, and what medicine you're requesting.

Pick a doctor or let us assign

Choose a specialist or we'll match you with the next available doctor.

Doctor reviews your case

Usually within 30 minutes. They may ask follow-up questions via chat.

Collect from any pharmacy

Electronic prescription sent to your email — valid across Spain.

Frequently Asked Questions

Is a prescription required for Lacosamide Fresenius Kabi?

Lacosamide Fresenius Kabi requires a prescription in Poland. You can check with a doctor online whether this medicine may be appropriate for your situation.

What is the active substance in Lacosamide Fresenius Kabi?

The active ingredient in Lacosamide Fresenius Kabi is lacosamide. This information helps identify medicines with the same composition but different brand names.

Who manufactures Lacosamide Fresenius Kabi?

Lacosamide Fresenius Kabi is manufactured by Labesfal - Laboratórios Almiro, S.A.. Pharmacy brands and packaging may differ depending on the distributor.

Which doctors can assess the use of Lacosamide Fresenius Kabi online?

Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether Lacosamide Fresenius Kabi is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.

How to buy Lacosamide Fresenius Kabi in Spain?

Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.

You can buy Lacosamide Fresenius Kabi in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.

To obtain a prescription, you can use Oladoctor:

What are the alternatives to Lacosamide Fresenius Kabi?

Other medicines with the same active substance (lacosamide) include Lackepila, Lackepila, Lackepila. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.

LACOSAMIDE 10 mg /Ml Solution

Prescription review online

Talk to a doctor about this medicine

Sergey Ilyasov

How to use Lacosamide Fresenius Kabi

Package Leaflet: Information for the Patient

Lacosamide Fresenius Kabi, 10 mg/ml, Solution for Infusion

Read the Package Leaflet Carefully Before Using the Medication, as it Contains Important Information for the Patient.

Table of Contents of the Package Leaflet

Not sure if this medicine is right for you?

1. What is Lacosamide Fresenius Kabi and What is it Used For

What is Lacosamide Fresenius Kabi

What is Lacosamide Fresenius Kabi Used For

2. Important Information Before Using Lacosamide Fresenius Kabi

When Not to Use Lacosamide Fresenius Kabi

Warnings and Precautions

Children

Lacosamide Fresenius Kabi and Other Medications

Lacosamide Fresenius Kabi with Alcohol

Pregnancy and Breastfeeding

Driving and Operating Machines

Lacosamide Fresenius Kabi Contains Sodium

Started taking the medicine and have questions?

3. How to Use Lacosamide Fresenius Kabi

Using Lacosamide Fresenius Kabi

What Dose to Use

Adolescents and Children with a Body Weight of at Least 50 kg and Adults

Children and Adolescents with a Body Weight Below 50 kg

30 kg to below 50 kg:

Stopping Lacosamide Fresenius Kabi

4. Possible Side Effects

The Patient Should Inform Their Doctor or Pharmacist if They Experience Any of the Following Symptoms:

Additional Side Effects Related to Intravenous Infusion

Additional Side Effects in Children

Reporting Side Effects

5. How to Store Lacosamide Fresenius Kabi

6. Package Contents and Other Information

What Lacosamide Fresenius Kabi Contains

What Lacosamide Fresenius Kabi Looks Like and What the Package Contains

Marketing Authorization Holder

Manufacturer

This Medication is Authorized in the Member States of the European Economic Area and in the United Kingdom (Northern Ireland) Under the Following Names:

Information Intended for Healthcare Professionals Only:

Online doctors for Lacosamide Fresenius Kabi

Sergey Ilyasov

Ekaterina Agapova

Liubov Popova

Tetiana Radchuk

Areas of expertise

Get Lacosamide Fresenius Kabi Prescription Online

Frequently Asked Questions

Stay informed about Oladoctor